We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Hologic

Designs and provides products for clinical laboratory and blood screening, including testing items for detection of h... read more Featured Products: More products

Download Mobile App




Human Papilloma Virus Tests Compared and Evaluated

By LabMedica International staff writers
Posted on 29 Nov 2016
Print article
Image: The ThinPrep 2000 processor, an automated slide preparation system for use with the ThinPrep Pap test (Photo courtesy of Hologic).
Image: The ThinPrep 2000 processor, an automated slide preparation system for use with the ThinPrep Pap test (Photo courtesy of Hologic).
High-risk human papillomavirus testing is already part of cervical cancer screening programs in a number of countries and new tests need to be validated not only in clinical studies but also in routine screening settings with regard to their clinical performance.

As persistent infection with High-Risk Human Papillomaviruses (HR HPV) is a necessary risk factor for the development of (pre)-cancer, numerous HPV tests are nowadays commercially available to be used in cervical cancer screening programs. However, only a small number of these tests have been approved by the authorities.

Scientists at the University Hospital Tübingen (Germany) and their colleagues evaluated in a random sample of 1,456 patients from a German routine screening population of 13,372 women equal to or older than 30 years of age screened primarily by liquid-based cytology (LBC) that was complemented by 48 CIN3+ cases. Clinical sensitivities, relative specificities and positive predictive values (PPV) for both HPV tests were determined based on histologically confirmed high-grade cervical disease (CIN3+) as clinical outcome.

LBC was performed by the ThinPrep 2000 Processor (Hologic, Bedford, MA, USA) and cytology results were reported using the Munich Nomenclature II and were translated into The Bethesda System (TBS) LBC results were considered negative when the result was Pap I/II (Normal) or Pap IIw (ASC-US); all other results were considered positive. LBC samples were tested by Abbott RealTime High Risk HPV Test (RT hrHPV, Abbott Laboratories, Abbott Park, IL, USA). HPV genotyping was carried out using the INNO-LiPA HPV Genotyping Extra test (Fujirebio, Ghent, Belgium), which identifies 20 HPV genotypes.

The investigators found that HR HPV prevalence in residual LBC samples was found to be 5.4% by the RT hrHPV test and 5.6 % by the HR HC2 test, respectively. There was a high overall agreement between the RT hrHPV test and the HC2 assay for detection of HR HPV. Relative sensitivities for detection of CIN3+ in patients with abnormal cytology was 93.8 % for the RT hrHPV assay and 97.9 % for HC2. Relative specificities and PPVs were comparable for both tests. The highest PPV was calculated for the specific detection of HPV16 by the RT hrHPV test (84.2 %). The RT hrHPV test showed a reduced sensitivity for detection of HVP31-positive CIN3 +.

The authors concluded that that the sensitivities and relative specificities of the RT hrHPV and the HR HC2 test are comparable. However, it appears that the RT hrHPV test has a reduced sensitivity for the detection of HPV type 31, which in this study has led to two CIN3+ cases missed by the RT hrHPV test. A considerable benefit of the RT hrHPV HPV test is its separate type specific detection of the most prevalent HPV genotypes 16 and 18, which together account for a total of an estimated 70.4 % of cervical cancer cases worldwide. The study was published on November 11, 2016, in the journal BMC Infectious Diseases.

Related Links:
University Hospital Tübingen
Hologic
Abbott Laboratories
Fujirebio
Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.